| 43.26 -1.74 (-3.87%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 59.45  |
1-year : | 65.46 |
| Resists | First : | 50.9 |
Second : | 56.04 |
| Pivot price | 46.64 |
|||
| Supports | First : | 42.58 |
Second : | 35.42 |
| MAs | MA(5) : | 45.46 |
MA(20) : | 46.91 |
| MA(100) : | 36.25  |
MA(250) : | 29.1 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 14.9 |
D(3) : | 23.3 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 56.04 | Low : | 18.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VERA ] has closed below the lower bollinger band by 2.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 44.9 - 45.33 | 45.33 - 45.59 |
| Low: | 41.68 - 42.23 | 42.23 - 42.57 |
| Close: | 42.62 - 43.53 | 43.53 - 44.07 |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Sat, 31 Jan 2026
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Fri, 30 Jan 2026
Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? - Insider Monkey
Fri, 30 Jan 2026
Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? - Yahoo Finance UK
Thu, 29 Jan 2026
Y Intercept Hong Kong Ltd Buys New Shares in Vera Therapeutics, Inc. $VERA - MarketBeat
Thu, 29 Jan 2026
Vera Therapeutics, Inc. $VERA Shares Bought by J. Safra Sarasin Holding AG - MarketBeat
Thu, 29 Jan 2026
Is Vera Therapeutics (VERA) Attractive After Recent Share Price Pullback And DCF Upside? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 103.6 (%) |
| Shares Short | 8,460 (K) |
| Shares Short P.Month | 10,820 (K) |
| EPS | -4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -73.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -210 (M) |
| Levered Free Cash Flow | -127 (M) |
| PE Ratio | -10.85 |
| PEG Ratio | 0 |
| Price to Book value | 6.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|